16 1705-1716.Zipperer A. Konnerth M. C. Laux C. Berscheid A. Janek D. Weidenmaier C. Burian M. Schilling N. A. Slavetinsky C. Marschal M. Willmann M. Kalbacher H. Schittek B. Brotz- Oesterhelt H. Grond S. Peschel A. and Krismer B.

Springer Singapore.Wang M. Carver J. J. Phelan V. V. Sanchez L. M. Garg N. Peng Y. Nguyen D. D. Watrous J. Kapono C. A. Luzzatto-Knaan T. Porto C. Bouslimani A. Melnik A. V. Meehan M. J. Liu W.-T. Crusemann M. Boudreau P. D. Esquenazi E. Sandoval-Calderon M. Kersten R. D. Pace L. A. Quinn R. A. Duncan K. R. Hsu C.-C. Floros D. J. Gavilan R. G. Kleigrewe K. Northen T. Dutton R. J. Parrot D. Carlson E. E. Aigle B. Michelsen C. F. Jelsbak L. Sohlenkamp C. Pevzner P. Edlund A. McLean J. Piel J. MurphyB.

Maansson M. Keyzers R. A. Sims A. C. Johnson A. R. Sidebottom A. M. Sedio B. E. Klitgaard A. Larson C. B. Boya P C. A. Torres- Mendoza D. Gonzalez D. J. Silva D. B. Marques L. M. DemarqueD.

J. Tomasi S. Jenkins S. Macherla V. Hoffman T. Agarwal V. Williams P. G. Dai J. Neupane R. Gurr J. Rodriguez A. M. C. Lamsa A. Zhang C. Dorrestein K. Duggan B. M. Almaliti J. Allard P.-M. Phapale P. Nothias L.-F. Alexandrov T. Litaudon M. Wolfender J.-L. Kyle J. E. Metz T. O. Peryea T. Nguyen D.-T. VanLeer D. Shinn P. Jadhav A. Muller R. Waters K. M. Shi W. Liu X. Zhang L. Knight R. Jensen P. R. Palsson B. O. Pogliano K. Linington R. G. Gutierrez M. Lopes N. P. Gerwick W. H. Moore B. S. Dorrestein P. C. and Bandeira N. 2016 Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking.

Limited information is available on mortality rates of marine mammals from C. dif f icile infections however Clostridium species are relevant to cetaceans and have been isolated from intestinal and fecal samples from dolphins and whales.An emerging threat to humans this pathogen has limited treatment options with current therapy consisting of an aggressive dosage of vancomycin andor fecal transplants to try to re-establish microbiome health.Screening of phocoenami- cin against C. dif f icile ATCC 700057 according to CSLI guidelines revealed comparable activity MIC 2.6 mM to vancomycin MIC 2.9 mM.Biological Activity of Phocoenamicin Mimics Iono-phores.

31 391-398.Lessa F. C. Winston L. G. and McDonald L. C. 2015Burden of Clostridium dif f icile Infection in the United States.

C. and Gross C. A.

From these one isolate was selected for detailed chemical investigation resulting in the discovery of phocoenamicin a novel spirotetronate antibiotic with potent activity against MRSA and C. dif f icile.RESULTS AND DISCUSSIONSample Collection and Isolate Prioritization for Novel Bioactives Discovery.

Additionally a large coupling constant 10.2 Hz between H32 and H31b indicated an anti relationship  C. Considering the above correlations all four diastereomers were built and modeled in Discovery Studio 4.0.

This feature is observed in both phocoenamicin and fidaxomicin  a promising narrow spectrum antibiotic for treating C. dif f icile infections.

